Skip to Main Content

Paper Details

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Prostate Cancer Prostatic Dis
0
2023
Author NameAffiliation
Fred SaadUniversity of Montreal Health Center
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf
Derya TilkiUniversity Hospital Hamburg-Eppendorf
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf
Alberto BrigantiUrological Research Institute, IRCCS San Raffaele Scientific Institute
  • 1 - 5

Datasets

Release 1.2